文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

临床药物遗传学实施联盟（CPIC）关于二氢嘧啶脱氢酶基因型和氟嘧啶剂量的指南：2017 年更新。

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

机构信息

University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.

Department of Clinical Pharmacology, Division of Medical Oncology and Division of Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.

出版信息

Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.

DOI:10.1002/cpt.911
PMID:29152729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5760397/
Abstract

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

摘要

本指南的目的是提供有关二氢嘧啶脱氢酶 (DPYD) 基因型检测临床解读的信息，以便将结果用于指导氟嘧啶类药物（5-氟尿嘧啶和卡培他滨）的剂量调整。氟嘧啶类药物的使用详细指南、其临床药理学以及成本效益分析均不在本文件范围内。临床药物遗传学实施联盟 (CPIC) 指南考虑了已获得基因型数据的患者情况（更新信息可在 https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/ 上获取）。

相似文献

[1]
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.

Clin Pharmacol Ther. 2017-11-20

[2]
Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events.

Clin Transl Sci. 2021-7

[3]
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.

Eur J Hum Genet. 2020-4

[4]
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.

Clin Pharmacol Ther. 2013-8-29

[5]
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.

Pharmacogenomics. 2016-5

[6]
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

Eur J Cancer. 2016-2

[7]
The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.

Clin Colorectal Cancer. 2019-5-3

[8]
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.

Lancet Oncol. 2018-10-19

[9]
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.

Cancer Chemother Pharmacol. 2016-10

[10]
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.

Eur J Cancer. 2018-8-13

引用本文的文献

[1]
Key informant perspectives on pharmacogenomic (PGx) testing for antidepressant prescribing in primary care in Ontario, Canada: a qualitative description study.

BMJ Open. 2025-8-27

[2]
Implementation of and Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial.

JCO Precis Oncol. 2025-8

[3]
Molecular landscape of non-driver genes in myeloproliferative neoplasms through 333 cancer genes panel: Insights to reveal in Pakistan.

BMC Med Genomics. 2025-8-4

[4]
Preventing adverse drug reactions and more: current clinical use of pharmacogenetic testing.

Med Genet. 2025-7-17

[5]
Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?

Cancer Chemother Pharmacol. 2025-7-15

[6]
Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland.

Pharmacogenomics J. 2025-7-11

[7]
Real-world study on fluoropyrimidine-related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype-guided dosing.

Int J Cancer. 2025-6-19

[8]
SNP array analysis facilitates the identification of novel chromosomal alterations associated with disease and SNPs related to adverse drug reactions in neuroblastoma.

Oncol Lett. 2025-3-24

[9]
Precision Treatment of Patients With GI Cancer Using Pre-emptive Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil.

JCO Precis Oncol. 2025-6

[10]
DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews.

Pharmaceuticals (Basel). 2025-5-15

本文引用的文献

[1]
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.

Semin Oncol. 2017-2

[2]
Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.

Clin Pharmacol Ther. 2017-10

[3]
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?

Cancer Treat Rev. 2016-8-13

[4]
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.

Cancer Chemother Pharmacol. 2016-10

[5]
Pharmacokinetically guided algorithm of 5-fluorouracil dosing, a reliable strategy of precision chemotherapy for solid tumors: a meta-analysis.

Sci Rep. 2016-5-27

[6]
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.

Pharmacogenomics. 2016-5

[7]
Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.

Int J Cancer. 2016-2-19

[8]
DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial.

JAMA Oncol. 2016-5-1

[9]
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

Lancet Oncol. 2015-10-23

[10]
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

J Clin Oncol. 2015-11-16

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索